Mesoblast Ltd ADR (MESO)

[cjstocksup]

MESO - ARDs related MSC data

https://www.sciencedirect.com/science/article/pii/S2095809920300370


The study was not blinded and probably not randomized given the unusual ratio of treated (17) to control patients (44). All patients received anti-virals, most received antibiotics. A higher percentage of patients in the treated group received hepatic and renal support, despite similar baseline chemistry numbers in both groups. So, potential confounding variables. Treated patients did have a higher percentage with shock (dangerously low blood pressure) or treatment with extra-corporeal membrane oxygenation, markers for higher risk of mortality. Taking all that into consideration the results remain striking. Following treatment with MSC's patients survived at 3 times the rate of untreated patients (p=.006 indicating high statistical significance). Importantly, follow up on 4 patients at 5 years showed no evident adverse effects from treatment